Estimating effectiveness in an observational study: A case study of dornase alfa in cystic fibrosis

Journal of Pediatrics

Volumn 134, Issue 6, 1999, Pages 734-739

  Johnson, Charles A ^a,b,c   Butler, Steven M ^a,b,c   Konstan, Michael W ^a,b,c   Breen, Timothy J ^a,b,c   Morgan, Wayne J ^a,b,c  

^a GENENTECH INC   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORNASE ALFA;

ARTICLE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG RESEARCH; ENZYME THERAPY; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; LUNG FUNCTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPIROMETRY; TREATMENT OUTCOME;

EID: 0033510678     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(99)70290-8     Document Type: Article

References (15)

1. 1. Davis PB, Drumm M, Konstan MW. Cystic Fibrosis. Am J Resp Crit Care Med 1996;154:1229-56.
2. 2. Andersen DH. Cystic fibrosis of the pancreas and its relationship to celiac disease, a clinical and pathological study. Am J Dis Child 1938;56:344-99.
3. 3. Cystic Fibrosis Foundation, Patient Registry 1996 Annual Data Report. Bethesda, MD: 1997.
4. 4. Ramsey B. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-88.
5. 5. Koch C, Hoiby. N Pathogenesis of cystic fibrosis. Lancet 1993;341:1065-74.
6. 6. Chernick WS, Barbero GJ. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics 1959;24: 739-45.
7. 7. Regnis JA, Robinson M, Bailey D, Cook P, Hooper P, Chan HK, et al. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med 1994;150: 66-71.
8. 8. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331: 637-42.
9. 9. Cystic Fibrosis Foundation Guidelines for patients services, evaluation, and monitoring in cystic fibrosis centers. Am J Dis Child 1990;144:1311-2.
10. 10. Knudson R, Lebowitz M, Holberg C, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-34.
11. 11. SAS/STAT User's Guide. Version 6. Fourth Edition. Cary, NC: SAS Institute, Inc; 1994.
12. 12. Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997;41:161-5.
13. 13. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: pseudomonas aeruginosa infection. J Clin Epidemiol 1995;48:1041-9.
14. 14. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997; 131:1809-14.
15. 15. Schechter MS, Margolis PA. Relationship between socioeconomic status and disease severity in cystic fibrosis. J Pediatr 1998;132:260-4.